Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Seagen
Seagen
Pfizer takes $1.2B hit after assessing prospects of Seagen ADCs
Fierce Biotech
Tue, 02/4/25 - 09:55 am
Pfizer
earnings
Seagen
M&A
Former Seagen CEO's biotech raises $140M series A to ready PD1/VEGFR2 antibody for clinic
Fierce Biotech
Thu, 12/19/24 - 11:29 am
Seagen
Ottimo Pharma
funding
After Pfizer deal, former Seagen CEO returns to lead oncology startup
BioPharma Dive
Mon, 10/28/24 - 11:10 am
David Epstein
Ottimo Pharma
Seagen
oncology
cancer immunotherapy
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
BioSpace
Mon, 07/1/24 - 11:14 am
Daiichi Sankyo
Seagen
patents
Enhertu
Pfizer puts 74 Swiss jobs on chopping block as it folds Seagen into its cancer operations
Fierce Pharma
Thu, 05/9/24 - 07:18 pm
Pfizer
Seagen
layoffs
Switzerland
Emergence of ADCs as the “hot, new technology”
Pharmaphorum
Thu, 04/25/24 - 11:39 am
antibody-drug conjugate
Immunogen
AbbVie
Seagen
Pfizer
cancer
M&A
A two-decade bet on Seagen pays off
Stat
Mon, 04/15/24 - 11:03 am
Pfizer
Seagen
M&A
Pfizer's blood cancer therapy Adcetris succeeds in late-stage trial
Reuters
Tue, 03/12/24 - 11:08 am
Pfizer
Adcetris
lymphoma
clinical trials
Seagen
Seagen patent in Daiichi Sankyo ADC dispute nixed by USPTO News
Pharmaphorum
Wed, 01/17/24 - 09:38 am
Seagen
Daiichi Sankyo
patents
legal
Enhertu
USPTO
Seagen seeks new approval for Tukysa in HER2+ breast cancer
Clinical Trials Arena
Mon, 12/18/23 - 11:32 am
Seagen
Tukysa
breast cancer
HER2+ breast cancer
Pfizer Inks Potential $1B ADC Deal with Nona, Closes Seagen Acquisition
BioSpace
Fri, 12/15/23 - 11:35 am
Pfizer
Nona Biosciences
M&A
Seagen
solid tumors
Pfizer’s $43B Seagen Buy Clears Regulatory Hurdles, Plans Dec 14 Closing
BioSpace
Wed, 12/13/23 - 09:32 am
Pfizer
Seagen
M&A
Pfizer reveals reorganization, executive departure as it gets ready to close $43B Seagen buyout
Fierce Pharma
Tue, 12/12/23 - 11:23 am
Pfizer
Seagen
M&A
reorganization
Seagen reports positive data on Tukysa from Phase III breast cancer trial
Clinical Trials Arena
Thu, 12/7/23 - 11:02 am
Seagen
Tukysa
clinical trials
HER2-positive breast cancer
BMS chases Merck/Seagen with first-line bladder cancer filing
Pharmaphorum
Tue, 12/5/23 - 11:53 pm
Bristol Myers Squibb
Opdivo
bladder cancer
urothelial cancer
Merck
Seagen
FDA starts review of Padcev/Keytruda for bladder cancer
Pharmaphorum
Fri, 12/1/23 - 09:35 am
Merck
Astellas
Seagen
Padcev
bladder cancer
FDA
priority review
5 of the best paid biopharma CEOs
PharmaVoice
Mon, 11/13/23 - 10:10 am
Pharma CEOs
executive compensation
Sarepta Therapeutics
Royalty Pharma
Seagen
Zentalis
Pfizer
ESMO: Seagen and Genmab's Tivdak keeps cervical cancer patients alive longer
Fierce Pharma
Sun, 10/22/23 - 06:11 pm
ESMO
Pfizer
Seagen
cervical cancer
antibody-drug conjugate
Pfizer wins unconditional EU antitrust okay for $43 billion Seagen buy
Reuters
Thu, 10/19/23 - 10:45 pm
Pfizer
Seagen
M&A
Europe
ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer
Fierce Pharma
Wed, 10/18/23 - 11:42 am
Seagen
Astellas
Merck
Padcev
Keytruda
bladder cancer
ESMO
Pages
1
2
3
4
5
6
next ›
last »